News

Press Releases

Proclara Biosciences Announces $47 Million in New Investment to Support the Development of Product Candidates in Alzheimer’s, Parkinson’s and Other Diseases
September 07, 2016

Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease
September 07, 2016
 

Note: prior to September, 2016, Proclara Biosciences was known as NeuroPhage Pharmaceuticals.

 

NeuroPhage’s NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer’s Association International Conference
July 19, 2015

NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference
July 13, 2015

NeuroPhage to Participate on Neuroscience Drug Development Panel at MassBio Annual Meeting March 27, 2015
March 20, 2015

NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases
March 16, 2015

NeuroPhage Expands Series D Financing to $27 Million
January 14, 2015

In the News

New clues to target Alzheimer’s found in proteins
Shirley S. Wang, Wall Street Journal
July 20, 2015

Alzheimer’s drugs in the works might treat other diseases, too
Jon Hamilton, NPR
July 22, 2015

Universal plaque-busting drug could treat various brain diseases
Andy Coghlan, New Scientist
July 11, 2015

The bright side of Parkinson’s
John Palfreman, New York Times
February 21, 2015